Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease

  • Bioorg Med Chem Lett. 2015 Sep 1;25(17):3661-4. doi: 10.1016/j.bmcl.2015.06.046.
Jing Zhang  1 ,  Jan Romero  2 ,  Audrey Chan  2 ,  Jennifer Goss  2 ,  Sabrina Stucka  2 ,  Jason Cross  2 ,  Brian Chamberlain  2 ,  Mustafa Varoglu  2 ,  Haoqun Chandonnet  2 ,  Dominic Ryan  2 ,  Blaise Lippa  2
Affiliations
  • 1. Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, United States. Electronic address: [email protected].
  • 2. Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, United States.
PMID: 26117562 DOI: 10.1016/j.bmcl.2015.06.046
Abstract

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key Chemokine Receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.

Keywords
CCR9; Crohn’s disease; IBD; Sulfonamide; Ulcerative colitis.
Products